Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Aims To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM). Methods We conducted a post hoc analysis of data from a phase III trial in patients with T2DM and hypertension receiving 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2015-12, Vol.17 (12), p.1180-1193
Hauptverfasser:	Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., Johansen, O. E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antidiabetics Arteriosclerosis - complications Arteriosclerosis - epidemiology Arteriosclerosis - prevention & control Benzhydryl Compounds - administration & dosage Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Biomarkers Blood pressure Blood Pressure - drug effects Blood Pressure Monitoring, Ambulatory cardiovascular disease Clinical trials Cohort Studies Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Angiopathies - epidemiology Diabetic Angiopathies - prevention & control Dose-Response Relationship, Drug Female Glucosides - administration & dosage Glucosides - adverse effects Glucosides - therapeutic use Heart rate Heart Rate - drug effects Humans Hypertension - complications Hypertension - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Male Middle Aged Original phase III study Placebos Risk SGLT2 inhibitor type 2 diabetes Vascular Resistance - drug effects Vascular Stiffness - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM). Methods We conducted a post hoc analysis of data from a phase III trial in patients with T2DM and hypertension receiving 12 weeks' empagliflozin and four phase III trials in patients with T2DM receiving 24 weeks' empagliflozin (cohort 1, n = 823; cohort 2, n = 2477). BP was measured using 24‐h BP monitoring (cohort 1) or seated office measurements (cohort 2). Results Empagliflozin reduced systolic BP (SBP) and diastolic BP in both cohorts (p
ISSN:	1462-8902 1463-1326
DOI:	10.1111/dom.12572